Jazz Pharmaceuticals (JAZZ): Upside Is Clear - Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Jazz Pharmaceuticals (JAZZ) PT Lowered to $174 at Deutsche Bank; 'Decent Q, 2017 shaping up nicely'
May 10, 2017 9:06 AM EDTDeutsche Bank lowered its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $174.00 (from $176.00) while maintaining a Buy rating.
... More